Cargando…

Killing from within

Interleukin-10 (IL-10) is considered to be an immunosuppressive cytokine. However, the continuous administration of pegylated IL-10 (PEG-IL10) leads to the rejection of large, firmly established and metastatic syngeneic tumors. PEG-IL10 therapy induces the expansion and activation of intratumoral, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mumm, John B., Emmerich, Jan, Oft, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525615/ https://www.ncbi.nlm.nih.gov/pubmed/23264906 http://dx.doi.org/10.4161/onci.21423

Ejemplares similares

Autochthonous T cells to the rescue: IL-10 directly activates tumor-resident CD8(+) T cells
por: Emmerich, Jan, et al.
Publicado: (2012)

PNP inhibitors selectively kill cancer cells lacking SAMHD1
por: Davenne, Tamara, et al.
Publicado: (2020)

How imiquimod licenses plasmacytoid dendritic cells to kill tumors
por: Holcmann, Martin, et al.
Publicado: (2012)

License to kill: microsatellite instability and immune contexture
por: Maby, Pauline, et al.
Publicado: (2021)

Inducing DNA damage through R-loops to kill cancer cells
por: Lam, Fred C., et al.
Publicado: (2020)

Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
por: Choi, Bryan D, et al.
Publicado: (2013)

CDK1/2/5 blockade: killing two birds with one stone
por: Liu, Jiao, et al.
Publicado: (2021)

Anticancer Tc9 cells: Long-lived tumor-killing T cells for adoptive therapy
por: Lu, Yong, et al.
Publicado: (2014)

Smac mimetics combined with innate immune stimuli create the perfect cytokine storm to kill tumor cells
por: Beug, Shawn T, et al.
Publicado: (2014)

Sp3-cificity of TNF-α expression promotes the Smac mimetic-mediated killing of cancer cells
por: Beug, Shawn T., et al.
Publicado: (2019)

Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells: Killing two birds with one stone
por: Riganti, Chiara, et al.
Publicado: (2013)

Killing two birds with one stone: Blocking the mitochondrial pyruvate carrier to inhibit lactate uptake by cancer cells and radiosensitize tumors
por: Linden, Catherine Vander, et al.
Publicado: (2018)

What does not kill you makes you stronger: surviving anti-cancer therapies by cytoskeletal remodeling and Myosin II reactivation
por: Orgaz, Jose L, et al.
Publicado: (2020)

TAM macrophages promote growth and metastasis within the cancer ecosystem
por: Zarif, Jelani C, et al.
Publicado: (2014)

How often is each gene mutated within the cancer patient population?
por: Mendiratta, Gaurav, et al.
Publicado: (2022)

Within tumors, interactions between T cells and tumor cells are impeded by the extracellular matrix
por: Salmon, Hélène, et al.
Publicado: (2012)

Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade
por: Duraiswamy, Jaikumar, et al.
Publicado: (2013)

Oxysterols recruit tumor-supporting neutrophils within the tumor microenvironment: The many facets of tumor-derived oxysterols
por: Raccosta, Laura, et al.
Publicado: (2013)

Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment
por: Ménétrier-Caux, Christine, et al.
Publicado: (2012)

p85α neomorphic mutants: splitting away from the canonical path
por: Cheung, Lydia WT, et al.
Publicado: (2015)

PTHrP, its receptor, and protein kinase A activation in osteosarcoma
por: Walkley, Carl R, et al.
Publicado: (2014)

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
por: John, Liza B, et al.
Publicado: (2013)

JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia
por: de Bock, Charles E., et al.
Publicado: (2018)

Invadopodia formation in blood clots: Not so SLUGgish after all
por: Knowles, Lynn M, et al.
Publicado: (2014)

Lenalidomide induces degradation of IKZF1 and IKZF3
por: Krönke, Jan, et al.
Publicado: (2014)

Egfl7 promotes tumor escape from immunity
por: Pinte, Sébastien, et al.
Publicado: (2012)

Escape from senescence: revisiting cancer therapeutic strategies
por: Zampetidis, Christos P., et al.
Publicado: (2022)

PD-L1 immune suppression in cancer: Tumor cells or host cells?
por: Kleinovink, Jan Willem, et al.
Publicado: (2017)

Gut microbiota and colon cancer: the carbohydrate link
por: Belcheva, Antoaneta, et al.
Publicado: (2014)

The double-edge sword effect of anti-CD73 cancer therapy
por: Stagg, John
Publicado: (2012)

Getting by with a little help from the right CD4(+) T cells
por: Hoepner, Sabine, et al.
Publicado: (2013)

Trabectedin: A drug from the sea that strikes tumor-associated macrophages
por: Allavena, Paola, et al.
Publicado: (2013)

TAK1 safeguards endothelial cells from gut microbes and inflammation
por: Naito, Hisamichi, et al.
Publicado: (2019)

Different cell fates after mitotic slippage: From aneuploidy to polyploidy
por: Ohashi, Akihiro
Publicado: (2015)

Biomimetic human bone marrow tissues: models to study hematopoiesis and platforms for drug testing
por: García-García, Andrés, et al.
Publicado: (2021)

Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens
por: Scanlon, Christina Springstead, et al.
Publicado: (2013)

Mimotope vaccine efficacy gets a "boost" from native tumor antigens
por: Buhrman, Jonathan D., et al.
Publicado: (2013)

The macrophage: Switches from a passenger to a driver during anticancer therapy
por: Wang, Tao, et al.
Publicado: (2015)

A path from melanocyte stem cells to cutaneous melanoma illuminated by UVB
por: Moon, Hyeongsun, et al.
Publicado: (2018)

Revisiting glucose metabolism in cancer: lessons from a PKM knock-in model
por: Sato, Taku, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ek64rqp8gda9va2tbf1c32q3jb